GENE ONLINE|News &
Opinion
Blog

2022-08-11| M&A

Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition

by Max Heirich
Share To

On August 11, AstraZeneca announced the completion of its acquisition of TeneoTwo. TeneoTwo brings TNB-486 with it, a clinical-stage treatment for B-cell haematologic malignancies. Announced early this year, AstraZeneca paid $100 million upfront, with another $805 million related to potential R&D milestones.

Related Article: AstraZeneca Acquires Caelum in $500m Deal to Strengthen Rare Diseases Division

An Acquisition Leads To Another Acquisition

TeneoTwo spawned as an affiliate company of Tenobio after its own acquisition by Amgen for $900 million. A part of the deal struck included Tenobio splitting some of its assets into new companies. The newly formed TenoTwo received the asset TNB-486.

T-cell engagers are an emerging class of antibodies for treating certain solid tumors. They harness the host’s T-cells to recognize and kill cancer cells. TNB-486 is CD19/CD3 T-cell engager for the treatment of B-cell haematologic malignancies. A comparable treatment is Amgen’s BLINCYTO™ (blinatumomab), which gained FDA approval in 2014. 

Due to the potential of TNB-486, AstraZeneca sought to acquire the spin-off biotech company. In July of this year, they announced they had entered an agreement with TeneoTwo to purchase the company for their new treatment. 

AstraZeneca Pays $100 million up front

For the outstanding equity of TeneoTwo, AstraZeneca paid $100 million upfront. In addition, they agreed to pay an additional $805 million related to R&D milestones. The agreement also lists an additional $305 million in payments made for contingent commercial-related milestones to former equity holders. 

From now on, AstraZeneca will facilitate the program currently testing TNB-486. The Phase I clinical study effectively started on March 2, 2021. At this time, its primary completion date is estimated sometime around August 2023, with its total completion estimated around May 2024. The trial aims to evaluate the safety, clinical pharmacology, and clinical activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received two or more prior lines of therapy.

Along with AstraZeneca’s acquisition of Alexion, the acquisition of TeneoTwo marks another instance of the company seeking to treat rare diseases. 

Related Article: Catalent Scoops Up Fellow CDMO, Metrics, for $475 Million

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
Ajinomoto to Acquire Forge Biologics for $620 Million to Boost Gene Therapy Capabilities
2023-11-14
M&A
Strides Pharma to Sell Manufacturing Facility in Cost Optimization Move
2023-10-31
M&A
Novo Nordisk Acquires Ocedurenone with $1.3B for Hypertension and Cardiovascular Disease
2023-10-18
LATEST
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
Discrimination Leads to Rapid Aging, Science Shows the Detrimental Effects of this Act
2024-05-17
A New Study has Linked Treatment Resistant Depression to Body Mass Index
2024-05-16
AI Reveals Sex-Related Brain Differences and Precision Medicine Potential
2024-05-16
The EU Sustainability Directive’s Influence on Pharmaceutical Supply Chains
2024-05-15
New UC Berkeley Study Challenges Traditional Views on Lactate and Carbohydrate Metabolism
2024-05-15
First Person to Receive Transplanted Pig Kidney has Died
2024-05-13
EVENT
Scroll to Top